Phase 1 (M15-913): ABBV-621, a TRAIL Receptor Agonist, in Patients With Previously Treated Solid Tumors and Hematologic Malignancies

Key Inclusion Criteria

- R/R Solid tumor, AML or NHL
- ≥1 prior systemic therapy
- Solid tumors only: Measurable disease per RECIST 1.1
- ECOG PS 0-2
- Adequate hematologic, renal and hepatic function

Key Exclusion Criteria

- Uncontrolled brain metastases
- History of cirrhosis

Endpoints

Primary: MTD, RP2D, PK
Secondary: DLT, QTcF change from baseline
Exploratory: Response Rate

AbbVie-621 is an investigational drug that is not approved by the FDA or any regulatory health agency. Safety and efficacy have not been established.

Venetoclax is being investigated for indications that have not been approved by Regulatory Agencies. Safety and Efficacy have not been established in unapproved indications.

To learn more about these studies, please visit https://ClinicalTrials.gov or email abbvieclinicaltrials@abbvie.com